Delta Variant Spike RBD SARS-CoV-2

• Description:

  Delta Variant Spike RBD SARS-CoV-2_x000D_ Catalog number: B2010480_x000D_ Lot number: Batch Dependent_x000D_ Expiration Date: Batch dependent_x000D_ Amount: 100 ug_x000D_ Molecular Weight or Concentration: 27 kDa_x000D_ Supplied as: Lyophilized powder_x000D_ Appearance: Powder_x000D_ Applications: highly pure (> 95%) SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293 and has been tested for its ability to bind the human cellular receptor ACE2._x000D_ Storage: -20C_x000D_ Keywords: Delta RBD, Delta Spike_x000D_ Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um._x000D_ _x000D_ Download SARS-CoV-2 Brochure_x000D_ _x000D_ References:_x000D_ 1: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312._x000D_ _x000D_ 2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, Muecksch F,_x000D_ Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,_x000D_ Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,_x000D_ Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies_x000D_ by SARS-CoV-2 spike protein variants. bioRxiv [Preprint]. 2020 Jul_x000D_ 22:2020.07.21.214759._x000D_ _x000D_ 3: Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z,_x000D_ Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan_x000D_ Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2_x000D_ antibodies from a convalescent donor associates with distinct epitopes on the_x000D_ RBD. Cell Rep. 2021 Feb 2;34(5):108699._x000D_ _x000D_ 4: McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, Beltramello M,_x000D_ Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J,_x000D_ Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Caroline Foo SY,_x000D_ Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti_x000D_ A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D. N-terminal domain_x000D_ antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv_x000D_ [Preprint]. 2021 Jan 14:2021.01.14.426475._x000D_ _x000D_ 5: Chakraborty S. Evolutionary and structural analysis elucidates mutations on_x000D_ SARS-CoV2 spike protein with altered human ACE2 binding affinity. Biochem_x000D_ Biophys Res Commun. 2021 Jan 1;534:374-380._x000D_ _x000D_ 6: Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, Meyer_x000D_ B, Rudich Y, Li C, Marton I, Dym O, Elad N, Lewis MG, Andersen H, Gagne M, Seder_x000D_ RA, Douek DC, Schreiber G. SARS-CoV-2 variant prediction and antiviral drug_x000D_ design are enabled by RBD in vitro evolution. Nat Microbiol. 2021 Aug 16._x000D_ _x000D_ 7: Kim S, Liu Y, Lei Z, Dicker J, Cao Y, Zhang XF, Im W. Differential_x000D_ Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern._x000D_ bioRxiv [Preprint]. 2021 Jul 26:2021.07.23.453598._x000D_ _x000D_ 8: Carnell GW, Ciazynska KA, Wells DA, Xiong X, Aguinam ET, McLaughlin SH,_x000D_ Mallery D, Ebrahimi S, Ceron-Gutierrez L, Asbach B, Einhauser S, Wagner R, James_x000D_ LC, Doffinger R, Heeney JL, Briggs JAG. SARS-CoV-2 Spike Protein Stabilized in_x000D_ the Closed State Induces Potent Neutralizing Responses. J Virol. 2021 Jul_x000D_ 12;95(15):e0020321._x000D_ _x000D_ 9: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes_x000D_ BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn_x000D_ GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to_x000D_ neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv_x000D_ [Preprint]. 2021 Jan 29:2021.01.27.428516._x000D_ 10: Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S,_x000D_ Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and_x000D_ Implications of New Viral Variants. Front Immunol. 2021 Jul 12;12:701501. _x000D_ _x000D_ Products Related to Delta Variant SARS-CoV-2 Spike RBD : SARS-CoV-2

• Short Description:

  Catalog Number: B2010480 (100 ug)_x000D_ Delta Variant SARS-CoV-2 Spike RBD is a highly pure (> 95%) SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293 and has been tested for its ability to bind the human cellular receptor ACE2. Custom bulk orders of this product are available upon request._x000D_

• Weight:

  0.15

• Length:

  2

• Width:

  0.5

• Height :

  0.5